Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

Core Viewpoint - Arvinas, Inc. has announced the promotion of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer, reflecting their significant contributions to the company's success and its evolution in the biotechnology industry [1][2]. Group 1: Leadership Changes - Ian Taylor has been with Arvinas for eight years, previously serving as Chief Scientific Officer and Vice President of Pharmacology and Translational Medicine, and will now oversee the company's broad pipeline in his new role [2][3]. - Angela Cacace has been promoted to Chief Scientific Officer after serving as Vice President of Neuroscience and Platform Biology, where she played a key role in advancing the company's research capabilities [2][3]. Group 2: Contributions and Future Directions - Dr. Taylor emphasized the strength of Arvinas' clinical portfolio and research pipeline, expressing confidence in the company's future and its commitment to bringing PROTAC® protein degraders to patients [3][4]. - Dr. Cacace highlighted her commitment to fostering a collaborative environment to advance the company's pipeline and integrate scientific efforts with business strategy, aiming to translate research into impactful treatments [4]. Group 3: Company Overview - Arvinas is a clinical-stage biotechnology company focused on developing therapies through its PROTAC® platform, which targets and degrades disease-causing proteins [5]. - The company is advancing multiple investigational drugs, including vepdegestrant for ER+/HER2- breast cancer, ARV-102 for neurodegenerative disorders, and ARV-393 for non-Hodgkin lymphoma [5].